European Journal of Nuclear Medicine

, Volume 8, Issue 11, pp 491–494 | Cite as

97Ru-transferrin uptake in tumor and abscess

  • P. Som
  • Z. H. Oster
  • K. Matsui
  • G. Guglielmi
  • B. R. R. Persson
  • M. L. Pellettieri
  • S. C. Srivastava
  • P. Richards
  • H. L. Atkins
  • A. B. Brill
Article

Abstract

The uptake of97Ru-transferrin (Ru-TF) in tumor and abscess bearing animals was compared with67Ga-citrate (Ga),123I-transferrin (I-TF), and several other plasma proteins. Maximal concentration in tumor of Ru-TF in mice was three times higher than67Ga-citrate (16.80±4.20 vs 5.08±0.58% D/g) although it occurred later (24 h compared with67Ga which reached its maximum 2 h after injection). Whole body autoradiography (WBARG) with103Ru-transferrin (103Ru-TF) in tumor and abscess bearing rats demonstrated details of the distribution within these lesions. Turpentine-induced abscesses in the rabbits could be visualized with the gamma camera as early as 30 min post-injection of Ru-TF. It seems, therefore, that Ru-TF can be used for tumor and abscess localization. The results indicate that Ru-TF may have some advantages over67Ga-citrate because of the higher concentration in the lesions.123I-transferrin reached a concentration in tumor similar to67Ga (6.89±1.67 vs 5.08±0.58% D/g) but had a very low tumor to blood ratio (0.64). The three compounds investigated (Ru-TF, I-TF and ionic Ga, which binds instantaneously to TF in vivo) have a common lignad, transferrin. It appears, therefore, that tumor affinity is a property of the radionuclide-ligand complex rather than of the radionuclide itself.

Keywords

Public Health Radionuclide Nuclear Medicine Maximal Concentration Plasma Protein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chen DCP, Newman B, Turkall RM, Tsan MF (1982) Transferrin receptors and gallium-67 uptake in vitro. Eur J Nucl Med 7:536–540Google Scholar
  2. 2.
    Oster ZH, Som P, Gil MC (1981) Ru-97-DTPA: A new radiopharmaceutical for cisterography. J Nucl Med 22:269–273Google Scholar
  3. 3.
    Oster ZH, Som P, Gil MC (1981) Ru-97-DMSA for delayed renal imaging. Radiology 141:185–190Google Scholar
  4. 4.
    Schachner ER, Gil MC, Atkins HL (1981) Ru-97-Hepatobiliary agents for delayed studies of the biliary tract. 1: Ru-97-PIPIDA- J Nucl Med 22:352–357Google Scholar
  5. 5.
    Som P, Oster ZH, Fairchild RG (1981) Biodistribution of Ru-97 labeled DTPA, DMSA and transferrin. In: Third International Radiopharmacentical Dosimetry Symposium. HHS Publication FDA 81-8166, pp 346–363Google Scholar
  6. 6.
    Som P, Oster ZH, Matsui K (1981) Comparative uptake of clotting factors in experimental animals. J Nucl Med 22:55Google Scholar
  7. 7.
    Som P, Oster ZH, Yonekura Y, Meyer MA, Fand J, Brill AB (1982) Applications of whole body autoradiographic technique in radiopharmaceutical research. In: Proceedings 3rd World Congress Nucl Med Biol. Vol IV, Raynaud C (ed) Pergamon Press, Paris, pp 3257–3261Google Scholar
  8. 8.
    Srivastava SC, Richards P, Meinken GE, Larson SM, Grunbaum Z (1981) Tumor uptake of radioruthenium compounds. In: Radiopharmaceuticals: Structure activity relationship. Spencer R (ed), Grune and Stratton, New York, pp 207–223Google Scholar
  9. 9.
    Srivastava SC, Richards P, Meinken GE, Atkins HL, Sewatkar A, Ku TH (1980) Ruthenium-97 labeled compounds-A new class of radiopharmaceuticals. In: Frontiers in Nuclear Medicine. Horst W, Wagner HN, Jr, Buchanan JW (eds). Berlin Heidelberg New York: Springer, pp 123–133Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • P. Som
    • 1
    • 2
    • 3
  • Z. H. Oster
    • 1
    • 2
    • 3
  • K. Matsui
    • 1
    • 2
    • 3
  • G. Guglielmi
    • 1
    • 2
    • 3
  • B. R. R. Persson
    • 1
    • 2
    • 3
  • M. L. Pellettieri
    • 1
    • 2
    • 3
  • S. C. Srivastava
    • 1
    • 2
    • 3
  • P. Richards
    • 1
    • 2
    • 3
  • H. L. Atkins
    • 1
    • 2
    • 3
  • A. B. Brill
    • 1
    • 2
    • 3
  1. 1.Brookhaven National LaboratoryUptonUSA
  2. 2.SUNY Stony BrookNew YorkUSA
  3. 3.Radiofysiska InstitutionenLundSweden

Personalised recommendations